Ge Li Pharmaceutical-B (01672) will present a full analysis of the Phase Ib study of ASC30 oral tablets, the Phase Ib study of ASC30 injectables, and the preclinical study of combined use of ASC31 and ASC47 at the ObesityWeek conference in 2025.

The China Fortune Finance APP reported that Gilead Pharmaceuticals-B (01672) announced that it will present multiple reports at the 2025 Obesity Week held in Atlanta, Georgia, USA in the form of posters, including a complete analysis of the IB period study of the ASC30 once-daily oral tablet, the IB period study of the ASC30 monthly injection, and preclinical studies of the combined use of ASC31 and ASC47.